All In Biotech

Drug Trial Radar · NCT05942625

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Studyto Evaluate the Safety, Tolerability and Pharmacokinetics of HS-10390 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

84

Planned (sponsor's estimate)

Start

May 23, 2023

Primary completion

Jun 30, 2024

Study completion Dec 30, 2024

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Jul 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.

Conditions

  • IgA Nephropathy
  • Focal Segmental Glomerulosclerosis

Interventions

  • HS-10390 tabletDrug

    Oral administration of specified dose of HS-10390

  • Placebo tabletDrug

    Oral administration of matching dose ofplacebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuationTime frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 28 (MAD)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongda Hospital, Affiliated to Southeast University

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.